cis-N-Substituted N-normetazocine enantiomers possess peculiar pharmacological profiles. Indeed, dextro enantiomers bind with high affinity 1 receptor while opposite enantiomers bind opioid receptors. In spite of their stereochemistry, cis-N-2-phenylethyl N-normetazocine (phenazocine) enantiomers showed mixed opioid/1 receptor profiles and a significant in vivo analgesia. To the best of our knowledge, there is no information available regarding the evaluation of 1 pharmacological profile in the antinociceptive effects of (+)- and (−)-phenazocine. Therefore, the present study was designed to ascertain this component by in vitro and in vivo studies.In particular, we tested the 1 affinity of both enantiomers by a predictive binding assay in absence or presence of phenytoin (DPH). Our results showed that DPH (1 mM) did not increase the 1 receptor affinity of (+)-and (−)-phenazocine (Ki = 3.8 ± 0.4 nM, Ki = 85 ± 2.0 nM, respectively) suggesting a 1 antagonist profile of both enantiomers. This 1 antagonistic component of two phenazocine enantiomers was corroborated by in vivo studies in which the selective 1 receptor agonist PRE-084, was able to unmask their 1 antagonistic component associated with the opioid activity.The 1 antagonistic component of (+)- and (−)-phenazocine may justify their analgesic activity and it suggests that they may constitute a useful scaffold to develop new ligands with this dual activity.

(+)-and (−)-Phenazocine enantiomers: evaluation of their dual opioid agonist/σ1 antagonist properties and antinociceptive effects

Prezzavento Orazio
;
Arena Emanuela;Turnaturi Rita;Parenti Carmela;Marrazzo Agostino;Catalano Roberto;Amata Emanuele;Pasquinucci Lorella;
2017-01-01

Abstract

cis-N-Substituted N-normetazocine enantiomers possess peculiar pharmacological profiles. Indeed, dextro enantiomers bind with high affinity 1 receptor while opposite enantiomers bind opioid receptors. In spite of their stereochemistry, cis-N-2-phenylethyl N-normetazocine (phenazocine) enantiomers showed mixed opioid/1 receptor profiles and a significant in vivo analgesia. To the best of our knowledge, there is no information available regarding the evaluation of 1 pharmacological profile in the antinociceptive effects of (+)- and (−)-phenazocine. Therefore, the present study was designed to ascertain this component by in vitro and in vivo studies.In particular, we tested the 1 affinity of both enantiomers by a predictive binding assay in absence or presence of phenytoin (DPH). Our results showed that DPH (1 mM) did not increase the 1 receptor affinity of (+)-and (−)-phenazocine (Ki = 3.8 ± 0.4 nM, Ki = 85 ± 2.0 nM, respectively) suggesting a 1 antagonist profile of both enantiomers. This 1 antagonistic component of two phenazocine enantiomers was corroborated by in vivo studies in which the selective 1 receptor agonist PRE-084, was able to unmask their 1 antagonistic component associated with the opioid activity.The 1 antagonistic component of (+)- and (−)-phenazocine may justify their analgesic activity and it suggests that they may constitute a useful scaffold to develop new ligands with this dual activity.
2017
Sigma-1 receptor; (+)-Phenazocine; (−)-Phenazocine; Mechanical antinociception; Bifunctional ligands; Opioid
File in questo prodotto:
File Dimensione Formato  
EJMC-2017.pdf

solo gestori archivio

Licenza: Non specificato
Dimensione 1.25 MB
Formato Adobe PDF
1.25 MB Adobe PDF   Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11769/44901
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 42
  • ???jsp.display-item.citation.isi??? 40
social impact